title: The reproductive outcome of women with hypogonadotropic hypogonadism undergoing in vitro fertilization.
abstract: The aim of this study was to evaluate the reproductive outcome and assisted reproductive technology (ART) outcomes of patients with hypogonadotropic hypogonadism (HH) and to compare the results with male factor (MF) infertility patients. The reproductive outcome of 33 HH patients was evaluated retrospectively and compared with results of 47 patients with mild male factor infertility. For ovulation induction, human menopausal gonadotropin (hMG) was used in HH patients and recFSH was used in MF infertility patients. HH patients were divided into subgroups according to retrieved oocyte numbers and the groups were compared with each other. The main outcome measures were total gonadotropin dose used, duration of stimulation, human chorionic gonadotropin (hCG) day estradiol level and endometrial thickness, oocyte number retrieved, and rate of clinical pregnancy. ART outcomes and cycle characteristics of 33 HH patients were compared with 47 MF infertility patients. There was no difference in age and body mass index (BMI) between the groups, but mean follicle stimulating hormone FSH and luteinizing hormone LH levels were significantly lower in the HH group (p < 0.001). Duration of stimulation was 12.5 ± 2.06 days in the HH patients and 10.08 ± 1.62 days in the MF infertility patients and the difference was significant (p < 0.001). Total gonadotropin dose used was higher in the HH group than the MF infertility group (p < 0.001). However, there were no differences in hCG day estradiol levels, endometrial thickness on hCG day, total oocyte number retrieved, MII oocyte number, and pregnancy rate. In the HH subgroups, patient ages were significantly lower in the >15 oocyte retrieved group. Although patients with HH have a long-term estrogen deficiency, their response to controlled ovarian hyperstimulation treatment is similar to normal women. However, the HH group is heterogeneous and estimating the ovarian reserve before treatment is not always possible in this group.
authors.affiliation: Etlik Zubeyde Hanim Women Health Training and Research Hospital, Department of Reproductive Endocrinology and.
authors.forename: Saynur
authors.initials: S
authors.lastname: Yilmaz
authors.forename: A Seval
authors.initials: AS
authors.lastname: Ozgu-Erdinc
authors.forename: Omer
authors.initials: O
authors.lastname: Yumusak
authors.forename: Serkan
authors.initials: S
authors.lastname: Kahyaoglu
authors.forename: Berna
authors.initials: B
authors.lastname: Seckin
authors.forename: Nafiye
authors.initials: N
authors.lastname: Yilmaz
mesh_terms: D000328:Adult; D016022:Case-Control Studies; D006063:Chorionic Gonadotropin / Q000008:administration & dosage; D005260:Female; D005307:Fertilization in Vitro; D006801:Humans; D007006:Hypogonadism / Q000503:physiopathology*; D011247:Pregnancy; D018873:Pregnancy Rate
chemical_list: D006063:Chorionic Gonadotropin
keywords: ART outcome; clinical pregnancy rate; estimating ovarian reserve; hypogonadotropic hypogonadism